Neuro-Metabolic and Vascular Dysfunction as an Early Diagnostic for Alzheimer's Disease and Related Dementias.
CHIE, J. A. K. H. C.; PERSOHN, S. A.; PANDEY, R. S.; SIMCOX, O. R.; SALAMA, P.; TERRITO, P. R.
Show abstract
Alzheimers disease (AD) is the most prevalent neurodegenerative condition characterized by significant cognitive decline. Recent studies suggest that the brain undergoes anatomical and functional restructuring, resulting in neuro-metabolic and vascular dysregulation (MVD) prior to amyloid-{beta} accumulation, which begins at an early age and leads to the onset of AD. Using a retrospective clinical population (N=403) of subjects with varying disease stages from the Alzheimers Disease Neuroimaging Initiative (ADNI), we identified that disease progression follows a stage-dependent MVD pattern, facilitating the identification of at-risk and resilient brain regions. Although each region progresses at a different pace, regions associated with memory, cognitive tasks, and motor function showed significant early dysregulation. These changes aligned with transcriptomics and cognitive signatures. This study underscores that MVD in brain regions varies by sex and disease stage, making it a sensitive tool for early AD diagnosis. Furthermore, this approach could improve patient monitoring, stratification, and therapeutic testing.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- TREM2 Risk Variants with Alzheimer’s Disease Differ in Rate of Cognitive Decline 96%
- Tau-PET and in vivo Braak-staging as a prognostic marker in Alzheimer’s disease 96%
- Perivascular space enlargement accelerates with hypertension, white matter hyperintensities, chronic inflammation, and Alzheimer’s disease pathology: evidence from a three-year longitudinal multicentre study 96%
Similar papers in this journal
- Selective vulnerability and resilience to Alzheimer's disease tauopathy as a function of genes and the connectome 97%
- Default mode network tau predicts future clinical decline in atypical early Alzheimer’s disease 97%
- Glucose metabolism reflects local atrophy and tau pathology in symptomatic Alzheimer’s disease 97%
Similar papers in this journal
- Association of RDoC dimensions with post-mortem brain transcriptional profiles in Alzheimer’s Disease 95%
- Cross-sectional study of plasma phosphorylated Tau 217 in persons without dementia 95%
- Blood metabolites predicting Mild Cognitive Impairment in the Study of Latinos-Investigation of Neurocognitive Aging (HCHS/SOL) 95%
Similar papers in this journal
- Astrocyte biomarker signatures of amyloid-β and tau pathologies in Alzheimer’s disease 97%
- Individual regional associations between Aβ-, tau- and neurodegeneration (ATN) with microglial activation in patients with primary and secondary tauopathies 97%
- Cortical microstructural associations with CSF amyloid and pTau 97%